Search clinical trials for: KU-0059436 (AZD2281)(PARP inhibitor)

Total 682 results

AstraZeneca

Completed

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Ovarian Neoplasms | BRCA1 Protein | BRCA2 Protein

Netherlands, Belgium, United Kingdom, Poland
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer (ICEBERG 2)

Ovarian Neoplasm

United States, Spain, Australia, Germany, Sweden
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
AstraZeneca

Completed

Open Label, Dose Escalation Phase I Study of AZD2281

Advanced Solid Malignancies

Japan
National Cancer Institute (NCI)

Active, not recruiting

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...

United States
University of Washington
National Cancer Institute (NCI); AstraZeneca

Terminated

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
University of Washington
AstraZeneca

Terminated

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Primary Peritoneal High Grade Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IIIA Fallopian Tube Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); AstraZeneca

Completed

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
National Cancer Institute (NCI)

Recruiting

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Stage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Metastatic Bladder Carcinoma | Advanced Bladder Carcinoma | Advanced Genitourinary System Carcinoma | Metastatic Genitourinary System Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
The Christie NHS Foundation Trust
Clinical Trials Unit, Manchester

Completed

Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer (MOLTO)

Ovarian Cancer

United Kingdom
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

Melanoma Neoplasms

United States, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

Malignant Solid Tumors

United Kingdom
Lisette Nixon
AstraZeneca

Unknown

Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) (PIN)

Non-small Cell Lung Cancer

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Recruiting

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID)

Kidney Cancer | Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Kidney Cancer Metastatic | Renal Carcinoma

United States
CCTU- Cancer Theme
AstraZeneca; Cancer Research UK; University of Cambridge

Recruiting

WIRE - Novel Treatments in Renal Cell Cancer (WIRE)

Renal Cell Cancer

United Kingdom
University Health Network, Toronto
AstraZeneca

Completed

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Ovarian Cancer

Canada
Thomas Jefferson University
AstraZeneca

Active, not recruiting

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Recurrent Breast Carcinoma | Metastatic Malignant Neoplasm in the Chest Wall

United States
Beth Israel Deaconess Medical Center
Johns Hopkins University; Dana-Farber Cancer Institute; AstraZeneca

Active, not recruiting

Olaparib In Metastatic Breast Cancer

Metastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)

United States
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer (ICEBERG 1)

Breast Neoplasms

Sweden, United States, United Kingdom, Germany, Spain, Australia, Israel, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma

United States
The Netherlands Cancer Institute
AstraZeneca

Active, not recruiting

Olaparib and Radiotherapy in Head and Neck Cancer

Head and Neck Neoplasms | Carcinoma, Squamous Cell | Laryngeal Cancer Stage II | Laryngeal Cancer Stage III

Netherlands
The Netherlands Cancer Institute

Completed

Olaparib and Radiotherapy in Inoperable Breast Cancer

Locally Advanced Malignant Neoplasm | Triple-Negative Invasive Breast Carcinoma | Inflammatory Breast Carcinoma

Netherlands
The Methodist Hospital Research Institute
AstraZeneca

Recruiting

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Breast Cancer | Breast Cancer Metastatic

United States
Merck Sharp & Dohme LLC
AstraZeneca

Recruiting

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Advanced Solid Neoplasms

Japan, United States, Argentina, Australia, Canada, Colombia, Denmark, France, Guatemala, Ireland, Israel, Korea, Republic of, Mexico, Peru, Romania, Russian Federation, Spain, Switzerland, Turkey, United Kingdom, Italy
AstraZeneca

Active, not recruiting

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Advanced Ovarian Cancer | Paclitaxel | Carboplatin | Triple Negative Metastatic Breast Cancer

Belgium, Netherlands, United Kingdom
AstraZeneca

Completed

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

Pancreatic Neoplasms

United States, United Kingdom
OHSU Knight Cancer Institute
Oregon Health and Science University; Prospect Creek Foundation

Completed

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; American Association for... and other collaborators

Recruiting

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

Breast Inflammatory Carcinoma

United States, Canada, Puerto Rico
Cambridge University Hospitals NHS Foundation Trust
National Institute for Health Research, United Kingdom

Not yet recruiting

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Recruiting

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Ocular Melanoma | Uveal Melanoma

United States
National Cancer Institute (NCI)
AstraZeneca

Active, not recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Advanced Malignant Solid Neoplasm | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IIIA Lung Non-Small... and other conditions

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Recurrent Esophageal Carcinoma | Recurrent Gastric Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Carcinoma | Metastatic Gastric Carcinoma | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer... and other conditions

United States
Rahul Aggarwal
AstraZeneca

Recruiting

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Endometrial Cancer | Stage III Renal Cell Cancer | Locally Advanced Malignant Solid Neoplasm | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Stage IV... and other conditions

United States
Five Prime Therapeutics, Inc.

Completed

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Gastric Cancer | Advanced Solid Tumors | Transitional Cell Carcinoma of the Bladder

Korea, Republic of, United States, Taiwan
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca; The Marcus Foundation; McGuff Pharmaceuticals, Inc.

Recruiting

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI); AstraZeneca

Active, not recruiting

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
Roswell Park Cancer Institute
AstraZeneca

Active, not recruiting

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous Adenocarcinoma

United States
University of Washington
AstraZeneca

Active, not recruiting

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Biochemically Recurrent Prostate Carcinoma | Prostate Adenocarcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Bile Duct Adenocarcinoma | Fanconi Anemia Complementation Group Gene Mutation | Metastatic Bile Duct Carcinoma | PTEN Gene Deletion

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Triple Negative Breast Neoplasms

Colombia, United States, Canada, Chile, France, Germany, Hungary, Ireland, Japan, Korea, Republic of, Poland, Spain, Taiwan, Ukraine, United Kingdom
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Recruiting

Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer

Unresectable Malignant Solid Neoplasm | Endometrial Serous Adenocarcinoma | Metastatic Malignant Solid Neoplasm

United States

Search clinical trials for: KU-0059436 (AZD2281)(PARP inhibitor)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations